| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Greenwich Lifesciences, Inc. (GLSI) has 1 insider with recent SEC Form 4 filings, including 10 buys and 0 sells. GLSI is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 5.61M | $80.75M | +7.3K |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 13, 2023 | Thompson Jaye53 | VP Clinical Reg Affairs | Buy | 250 | $9.49 | $2,372.50 | - | -4.2% | +65.3% | |
| May 17, 2023 | Patel Snehal61 | CEO And CFO | Buy | 1,000 | $11.69 | $11,690.00 | - | -9.2% | +23.1% | |
| Apr 28, 2023 | Thompson Jaye53 | VP Clinical Reg Affairs | Buy | 250 | $11.22 | $2,805.00 | - | -16.5% | +22.5% | |
| Apr 19, 2023 | Patel Snehal61 | CEO And CFO | Buy | 7,000 | $11.10 | $77,700.00 | +0.1% | -16.8% | +15.6% | |
| Apr 18, 2023 | Patel Snehal61 | CEO And CFO | Buy | 2,000 | $11.12 | $22,240.00 | - | -15.4% | +17.1% | |
| Apr 11, 2023 | Thompson Jaye53 | VP Clinical Reg Affairs | Buy | 1,000 | $11.87 | $11,870.00 | +0.4% | -25.4% | +29.6% | |
| Apr 11, 2023 | Patel Snehal61 | CEO And CFO | Buy | 5,000 | $12.42 | $62,100.00 | - | -25.4% | +29.6% | |
| Mar 15, 2023 | Thompson Jaye53 | VP Clinical Reg Affairs | Buy | 250 | $12.71 | $3,177.50 | - | -13.4% | +27.8% | |
| Mar 10, 2023 | Patel Snehal61 | CEO And CFO | Buy | 1,000 | $12.12 | $12,120.00 | - | -4.8% | +26.7% | |
| Feb 24, 2023 | Thompson Jaye53 | VP Clinical Reg Affairs | Buy | 250 | $15.40 | $3,848.75 | - | -26.9% | -12.5% |